Autolus Therapeutics plc
AUTLHealthcare|Biotechnology|GB
$1.28
+0.02 (+1.59%)
Tangible Book / Share
$0.21
Cash / Share
$0.76
Financials
Financial Snapshot
Market Cap
$340.7M
Enterprise Value
$252.8M
Revenue (TTM)
$117.4M
Net Income (TTM)
-$280.0M
Cash & Investments
$201.6M
Net Cash
$118.1M
Free Cash Flow (TTM)
-$237.4M
Operating CF (TTM)
-$225.6M
Debt/Equity
1.12
Cash Runway & Burn Rate
Cash on Hand
$201.6M
Quarterly Burn
$56.4M
Monthly Burn
$18.8M
Est. Runway
~3.6 quarters
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $28.1M | $137.1M | $189.3M | $211.4M | $154.1M | $310.3M | $382.4M | $239.6M | $588.0M | $300.7M | $201.6M | |
| Operating Cash Flow | -$9.8M | -$16.4M | -$25.8M | -$101.5M | -$117.8M | -$117.9M | -$112.3M | -$145.6M | -$206.3M | -$283.6M | -$225.6M | |
| Free Cash Flow | -$11.7M | -$19.2M | -$34.6M | -$120.2M | -$132.4M | -$126.7M | -$123.1M | -$156.6M | -$241.1M | -$310.7M | -$237.4M | |
| Capital Expenditure | -$1.9M | -$2.9M | -$8.8M | -$18.7M | -$14.7M | -$8.9M | -$10.8M | -$11.0M | -$34.8M | -$27.1M | -$11.8M | |
| Financing Cash Flow | $32.2M | $127.7M | $117.5M | $108.9M | $74.4M | $284.1M | $223.6M | -$883.0K | $589.6M | -$4.3M | -$7.8M |
R&D Spending
R&D (TTM)
$112.6M
R&D Intensity
95.9%
R&D Growth vs Prior
-12.4%
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.7M | $1.0M | $2.9M | $1.7M | $1.5M | $6.2M | $1.7M | $10.1M | $75.6M | $117.4M | |
| R&D Expense | $10.4M | $16.0M | $24.6M | $105.6M | $135.0M | $110.8M | $117.4M | $130.5M | $158.1M | $128.6M | $112.6M | |
| R&D % of Revenue | 861.1% | 945.8% | 2356.9% | 3632.0% | 7871.0% | 7354.9% | 1894.6% | 7684.4% | 1562.6% | 170.2% | 95.9% | |
| SG&A | $5.2M | $9.1M | $16.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | $0.00 | $131.8M | $153.1M |
Income Statement
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $1.7M | $1.0M | $2.9M | $1.7M | $1.5M | $6.2M | $1.7M | $10.1M | $75.6M | $117.4M | |
| Cost of Revenue | $478.0K | $1.0M | $48.3M | $105.4M | $134.9M | $0.00 | $0.00 | $0.00 | $141.0M | $96.6M | $99.0M | |
| Gross Profit | $734.0K | $684.0K | -$47.3M | -$102.5M | -$133.2M | $1.5M | $6.2M | $1.7M | -$130.9M | -$21.0M | $18.4M | |
| R&D | $10.4M | $16.0M | $24.6M | $105.6M | $135.0M | $110.8M | $117.4M | $130.5M | $158.1M | $128.6M | $112.6M | |
| SG&A | $5.2M | $9.1M | $16.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | $0.00 | $131.8M | $153.1M | |
| Operating Income | -$14.4M | -$23.4M | -$57.5M | -$247.6M | -$303.1M | -$140.4M | -$142.9M | -$179.7M | -$241.4M | -$281.4M | -$247.3M | |
| Interest Expense | $0.00 | $0.00 | $12.7K | $0.00 | $0.00 | $1.1M | $8.9M | $45.1M | $9.3M | $36.8M | $47.1M | |
| Pretax Income | -$14.3M | -$23.4M | -$36.3M | -$108.7M | -$166.3M | -$142.0M | -$148.6M | -$208.4M | -$219.1M | -$296.8M | -$279.3M | |
| Net Income | -$12.6M | -$19.7M | -$31.1M | -$123.8M | -$142.1M | -$142.1M | -$148.8M | -$208.4M | -$220.7M | -$288.2M | -$280.0M | |
| EPS (Diluted) | -0.91 | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 | -1.08 | -1.06 | |
| EBITDA | -$13.9M | -$22.4M | -$50.3M | -$137.4M | -$162.5M | -$132.5M | -$132.2M | -$156.8M | -$233.1M | -$250.3M | -$220.9M | |
| Shares Out. (M) | 13.78 | 13.78 | 31.56 | 43.07 | 51.56 | 72.08 | 94.99 | 173.94 | 255.16 | 266.14 | 266.16 |
Balance Sheet
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $28.1M | $137.1M | $189.3M | $211.4M | $154.1M | $310.3M | $382.4M | $239.6M | $227.4M | $104.1M | $171.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $360.6M | $196.6M | $30.2M | |
| Total Current Assets | $30.9M | $142.5M | $199.1M | $249.3M | $194.0M | $347.0M | $425.8M | $275.3M | $660.9M | $435.9M | $336.1M | |
| Total Assets | $34.2M | $148.7M | $217.7M | $303.5M | $294.2M | $405.6M | $490.3M | $375.4M | $782.7M | $589.1M | $493.2M | |
| Total Current Liabilities | $2.7M | $5.0M | $12.5M | $25.0M | $33.6M | $28.6M | $46.4M | $44.7M | $60.7M | $73.4M | $68.8M | |
| Long-Term Debt | $0.00 | $0.00 | $221.0K | $0.00 | $0.00 | $47.0M | $0.00 | $0.00 | $0.00 | $270.2M | $0.00 | |
| Total Liabilities | $3.5M | $6.1M | $12.5M | $48.7M | $84.2M | $92.2M | $191.6M | $263.9M | $355.4M | $410.9M | $418.4M | |
| Stockholders' Equity | $30.7M | $142.6M | $205.1M | $254.8M | $210.0M | $313.3M | $298.7M | $111.5M | $427.3M | $178.1M | $74.8M | |
| Retained Earnings | -$28.2M | -$47.9M | $163.8M | -$237.2M | -$379.2M | -$521.3M | -$670.2M | -$878.6M | -$1.10B | -$1.39B | -$1.50B |
Cash Flow Statement
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.8M | -$16.4M | -$25.8M | -$101.5M | -$117.8M | -$117.9M | -$112.3M | -$145.6M | -$206.3M | -$283.6M | -$225.6M | |
| Capital Expenditure | -$1.9M | -$2.9M | -$8.8M | -$18.7M | -$14.7M | -$8.9M | -$10.8M | -$11.0M | -$34.8M | -$27.1M | -$11.8M | |
| Free Cash Flow | -$11.7M | -$19.2M | -$34.6M | -$120.2M | -$132.4M | -$126.7M | -$123.1M | -$156.6M | -$241.1M | -$310.7M | -$237.4M | |
| Investing Cash Flow | -$1.9M | -$2.9M | -$7.6M | -$18.7M | -$14.7M | -$8.9M | -$10.8M | -$11.0M | -$394.6M | $158.5M | $286.1M | |
| Financing Cash Flow | $32.2M | $127.7M | $117.5M | $108.9M | $74.4M | $284.1M | $223.6M | -$883.0K | $589.6M | -$4.3M | -$7.8M | |
| Issuance of Stock | $32.2M | $127.7M | $128.7M | $115.9M | $79.8M | $245.9M | $163.9M | $0.00 | $550.0M | $0.00 | $3.0K | |
| Repurchase of Stock | $0.00 | $0.00 | -$3.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$2.1M | |
| Stock Based Comp. | $2.3M | $3.2M | $5.0M | $30.2M | $20.1M | $9.9M | $12.0M | $11.2M | $15.5M | $14.4M | $15.4M | |
| Net Change in Cash | $17.9M | $109.0M | $87.0M | -$6.1M | -$57.3M | $156.6M | $72.1M | -$142.4M | -$11.5M | -$123.2M | $47.6M |
Dilution Tracker
Shares outstanding grew 416.2% over 5 years — significant dilution
Shares Outstanding
266M
5-Year Share Growth
+416.2%
Stock Issuance (TTM)
$3.0K
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 13.78 | 13.78 | 31.56 | 43.07 | 51.56 | 72.08 | 94.99 | 173.94 | 255.16 | 266.14 | 266.16 | |
| Change vs Prior % | — | 0.0% | 129.0% | 36.5% | 19.7% | 39.8% | 31.8% | 83.1% | 46.7% | 4.3% | 0.0% | |
| Stock Issuance | $32.2M | $127.7M | $128.7M | $115.9M | $79.8M | $245.9M | $163.9M | $0.00 | $550.0M | $0.00 | $3.0K | |
| Stock Repurchase | $0.00 | $0.00 | -$3.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.3M | $3.2M | $5.0M | $30.2M | $20.1M | $9.9M | $12.0M | $11.2M | $15.5M | $14.4M | $15.4M |
Margins & Profitability
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 60.6% | 40.4% | -4520.4% | -3525.1% | -7765.2% | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% | 15.7% | |
| Operating Margin % | -1186.1% | -1383.2% | -5503.7% | -8513.8% | -17675.4% | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% | -210.8% | |
| Net Margin % | -1035.5% | -1165.2% | -2976.5% | -4258.9% | -8285.4% | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% | -238.6% | |
| EBITDA Margin % | -1146.7% | -1323.6% | -4813.9% | -4723.2% | -9474.5% | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% | -188.2% | |
| FCF Margin % | -965.7% | -1136.2% | -3311.7% | -4131.8% | -7722.4% | -8408.6% | -1988.2% | -9221.0% | -2382.3% | -411.2% | -202.3% | |
| ROE % | -40.9% | -13.8% | -15.2% | -48.6% | -67.7% | -45.4% | -49.8% | -186.9% | -51.6% | -161.8% | -178.6% | |
| ROA % | -36.7% | -13.3% | -14.3% | -40.8% | -48.3% | -35.0% | -30.4% | -55.5% | -28.2% | -48.9% | -56.8% | |
| ROIC % | -40.0% | -13.8% | -24.0% | -88.1% | -98.1% | -36.8% | -31.8% | -53.5% | -33.3% | -51.5% | -57.5% | |
| R&D / Revenue % | 861.1% | 945.8% | 2356.9% | 3632.0% | 7871.0% | 7354.9% | 1894.6% | 7684.4% | 1562.6% | 170.2% | 95.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1187.8% | 39.7% | -38.3% | 0.0% | -41.0% | -12.1% | 311.0% | -72.6% | 496.0% | 646.7% | |
| Gross Profit | 679.9% | -6.8% | -7008.4% | 0.0% | -29.9% | 101.1% | 311.0% | -72.6% | -7809.1% | 83.9% | |
| Operating Income | -77.3% | -62.9% | -145.7% | 0.0% | -22.4% | 53.7% | -1.8% | -25.8% | -34.3% | -16.6% | |
| Net Income | -68.1% | -57.2% | -57.7% | 0.0% | -14.7% | -0.0% | -4.7% | -40.0% | -5.9% | -30.6% | |
| EPS (Diluted) | -67.9% | -57.1% | 30.8% | 0.0% | 4.2% | 28.6% | 20.3% | 23.6% | 27.5% | -24.1% | |
| Operating Cash Flow | -196.2% | -66.1% | -58.0% | 0.0% | -16.0% | -0.1% | 4.7% | -29.6% | -41.7% | -37.5% | |
| Free Cash Flow | -186.3% | -64.4% | -80.0% | 0.0% | -10.2% | 4.3% | 2.8% | -27.1% | -54.0% | -28.9% | |
| R&D Expense | 380.3% | 53.4% | 53.9% | 0.0% | 27.8% | -17.9% | 5.9% | 11.2% | 21.2% | -18.7% | |
| SG&A Expense | -14.8% | 76.6% | 85.1% | 0.0% | -11.4% | -8.9% | 0.1% | 46.5% | -100.0% | 0.0% | |
| Total Assets | 50.9% | 334.9% | 46.4% | 0.0% | -3.1% | 37.8% | 20.9% | -23.4% | 108.5% | -24.7% | |
| Book Value / Share | 48.2% | 364.7% | -37.2% | 0.0% | -31.2% | 6.7% | -27.7% | -79.6% | 161.3% | -60.0% | |
| Debt | 0.0% | 41.0% | -16.6% | 0.0% | 106.6% | 25.6% | -64.3% | 118.4% | -0.6% | 568.0% | |
| Diluted Shares | 0.0% | 0.0% | 129.0% | 0.0% | 19.7% | 39.8% | 31.8% | 83.1% | 46.7% | 4.3% |
Valuation
P/E (TTM)At Loss
P/S2.90
10Y Low / Med / High7.01 / 248.25 / 924.97
P/B4.55
10Y Low / Med / High0.60 / 2.42 / 11.23
EV/EBITDAAt Loss
EV/Revenue2.15
10Y Low / Med / High10.28 / 131.79 / 744.09
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.21
Cash / Share
$0.76
| Metric | Trend | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -27.47 | -17.48 | -30.95 | -4.58 | -3.24 | -2.63 | -1.21 | -5.37 | -2.70 | -1.84 | -1.21 | |
| P/S Ratio | 284.31 | 203.53 | 924.97 | 195.48 | 268.76 | 248.25 | 29.14 | 659.71 | 59.25 | 7.01 | 2.90 | |
| P/B Ratio | 11.23 | 2.42 | 4.71 | 2.23 | 2.19 | 1.19 | 0.60 | 10.05 | 1.40 | 2.97 | 4.55 | |
| EV/EBITDA | -22.79 | -9.27 | -15.46 | -2.79 | -2.22 | -0.99 | 1.34 | -5.96 | -1.82 | -3.10 | -1.14 | |
| EV/Revenue | 261.31 | 122.73 | 744.09 | 131.79 | 210.50 | 87.45 | -28.69 | 549.82 | 41.98 | 10.28 | 2.15 |
Analyst Estimates & Quality
Altman Z-Score
-4.43
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $149.4M | $200.0M | $282.6M |
| Net Income | -$207.3M | -$168.7M | -$117.5M |
| EPS | $-0.78 | $-0.63 | $-0.44 |
| # Analysts (EPS) | 5 | 5 | 3 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Grant | $1.5M | $823.0K | $166.0K | — | — | — |
| License | $242.0K | $1.5M | $6.2M | $1.7M | $10.1M | $1.1M |
| Product | — | — | — | — | — | $74.3M |
By Geography
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| UNITED STATES | $1.5M | $6.2M | $1.4M | — | $1.0M |
| Europe | — | — | — | $10.1M | $50.0K |